Nutex Health reports 82% revenue growth for 2025
#Nutex Health #revenue growth #2025 #financial report #corporate earnings
📌 Key Takeaways
- Nutex Health achieved 82% revenue growth in 2025.
- The growth highlights significant expansion in the company's financial performance.
- The report indicates strong operational or market success for the year.
- This growth figure positions Nutex Health as a rapidly growing entity in its sector.
🏷️ Themes
Revenue Growth, Corporate Performance
📚 Related People & Topics
Nutex Health
American healthcare company
Nutex Health Inc. is an American for-profit health care company and operator of healthcare facilities headquartered in Houston, Texas.
Entity Intersection Graph
No entity connections available yet for this article.
Mentioned Entities
Original Source
try{ var _=i o; . if(!_||_&&typeof _==="object"&&_.expiry Oil extends weekly gains as Iran conflict rages on, with crude surging around 18% Trump replaces Homeland Security chief Kristi Noem Wall Street ends lower on escalating Iran conflict, report of AI export curbs Trump says he must be involved in selecting Iran’s next leader (South Africa Philippines Nigeria) Nutex Health reports 82% revenue growth for 2025 By Company News Published 03/05/2026, 06:40 PM Nutex Health reports 82% revenue growth for 2025 0 NUTX -2.86% HOUSTON - Nutex Health Inc. (NASDAQ:NUTX) reported total revenue of $875.3 million for 2025, an 82.4% increase from $479.9 million in 2024, according to a press release statement issued today. The physician-led healthcare company, which operates 27 hospital facilities across 12 states, generated $844.2 million from its hospital division, up 188% from $293.1 million in 2024. Approximately 63% of hospital revenue, or $527.8 million, related to higher acuity claims and success through the Independent Dispute Resolution process. Net income attributable to Nutex Health reached $70.8 million in 2025, compared to $52.1 million in 2024. The company reported diluted earnings per share of $10.48 for 2025 versus $9.69 for 2024. The stock trades at a P/E ratio of 6.28 with a market cap of $767 million, and InvestingPro analysis indicates the company is undervalued relative to its Fair Value . The platform assigns Nutex an "EXCELLENT" Financial Health score of 3.78, with comprehensive analysis available in its detailed Pro Research Report . Stock-based compensation expense totaled $117 million for 2025, compared to $16.6 million in the prior year. The company stated this included one-time obligations of earn-out shares for qualifying hospitals under construction. Operating cash flow reached $248.1 million for 2025. As of December 31, 2025, Nutex Health held cash and cash equivalents of $185.6 million and long-term debt of $29.2 million. Fourth quarter revenue dec...
Read full article at source